22.34

2.28% -0.4997

Ultragenyx Pharmaceutical Inc (RARE)

Overview News Price History Option Chain Financials Why RARE Down? Discussions Forecast Stock Split

Ultragenyx Pharmaceutical Inc stock is traded at $22.34, with a volume of 190.01K. It is down -2.28% in the last 24 hours and down -6.53% over the past month. Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Previous Close:

$22.84

Open:

$22.78

24h Volume:

190.01K

Relative Volume:

0.07

Market Cap:

$2.16B

Revenue:

$610.16M

Net Income/Loss:

$-532.93M

P/E Ratio:

-4.0408

EPS:

-5.5287

Net Cash Flow:

$-442.30M

1W Performance:

+2.39%

1M Performance:

-6.53%

6M Performance:

-28.53%

1Y Performance:

-41.77%

1-Day Range:

$22.14

$22.84

1-Week Range:

$20.61

$23.19

52-Week Range:

$18.41

$42.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Name

Ultragenyx Pharmaceutical Inc

Sector

Healthcare (1117)

Industry

Biotechnology (618)

Phone

415-483-8800

Address

60 LEVERONI COURT, NOVATO, CA

Employee

1,371

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

RARE's Discussions on Twitter

Compare RARE vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RARE Ultragenyx Pharmaceutical Inc	22.36	2.21B	610.16M	-532.93M	-442.30M	-5.5287
VRTX Vertex Pharmaceuticals Inc	493.00	126.81B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	773.75	81.62B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	734.26	45.97B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	319.75	42.76B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	300.21	33.88B	5.36B	287.73M	924.18M	2.5229

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Initiated	Wells Fargo	Overweight
Jul-28-25	Resumed	H.C. Wainwright	Buy
May-28-25	Initiated	William Blair	Outperform
Jun-06-24	Upgrade	Goldman	Neutral → Buy
Apr-22-24	Initiated	RBC Capital Mkts	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Jun-14-23	Resumed	Credit Suisse	Outperform
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight
Jan-18-23	Resumed	Canaccord Genuity	Buy
Dec-30-22	Resumed	H.C. Wainwright	Buy
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight
Sep-30-21	Initiated	H.C. Wainwright	Buy
Aug-19-21	Initiated	UBS	Sell
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy
Jun-04-21	Resumed	Robert W. Baird	Neutral
May-06-21	Upgrade	Citigroup	Neutral → Buy
May-06-21	Upgrade	Evercore ISI	In-line → Outperform
Apr-26-21	Resumed	Credit Suisse	Neutral
Mar-02-21	Resumed	Stifel	Buy
Feb-12-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-07-20	Downgrade	Wedbush	Outperform → Neutral
Nov-24-20	Resumed	Evercore ISI	In-line
Nov-12-20	Downgrade	BofA Securities	Buy → Neutral
Aug-02-19	Resumed	Wedbush	Outperform
Mar-27-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Feb-22-19	Resumed	Raymond James	Outperform
Jan-02-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-08-18	Upgrade	Citigroup	Sell → Neutral
Sep-10-18	Initiated	Morgan Stanley	Equal-Weight
Jun-21-18	Downgrade	Credit Suisse	Outperform → Neutral
May-11-18	Upgrade	Barclays	Equal Weight → Overweight
May-10-18	Initiated	Goldman	Neutral
Apr-18-18	Upgrade	SunTrust	Hold → Buy
Mar-22-18	Resumed	Piper Jaffray	Overweight
Feb-21-18	Reiterated	Stifel	Buy
Jan-22-18	Upgrade	Evercore ISI	In-line → Outperform
Jan-18-18	Initiated	Credit Suisse	Outperform
Dec-05-17	Reiterated	Barclays	Equal Weight
Dec-04-17	Upgrade	Jefferies	Hold → Buy
Sep-14-17	Upgrade	Wedbush	Neutral → Outperform

View All

Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News

12:07 PM

Insider Sell: Karah Parschauer Sells Shares of Ultragenyx Pharma - GuruFocus

12:07 PM

Mar 10, 2026

RARE Investors Have Opportunity to Lead Ultragenyx - GlobeNewswire

Mar 10, 2026

Investors who lost money on Ultragenyx Pharmaceutical Inc.(RARE) should contact The Gross Law Firm about pending Class ActionRARE - PR Newswire

Mar 10, 2026

Ultragenyx EVP Pinion sells $228k in shares - Investing.com Nigeria

Mar 10, 2026

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 10, 2026

Mar 09, 2026

Biopharma Brass Hid Drug Trial Risks, Derivative Suit Says - Law360

Mar 09, 2026

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - Financial Times

Mar 09, 2026

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ultragenyx - GlobeNewswire

Mar 09, 2026

Levi & Korsinsky, LLP: Institutional Investor Notice --- Ultragenyx Pharmaceutical Lead Plaintiff Opportunity - GlobeNewswire

Mar 09, 2026

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 5.6%Still a Buy? - MarketBeat

Mar 09, 2026

Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire

Mar 09, 2026

FinancialContentUltragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - FinancialContent

Mar 09, 2026

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Richtech Robotics Inc. (RR), Ultragenyx Pharmaceutical Inc. (RARE), and Mereo BioPharma Group plc (MREO) Announced by Holzer & Holzer, LLC - marketscreener.com

Mar 09, 2026

Mar 08, 2026

CLASS ACTION INVESTOR ALERTS: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ultragenyx and Mereo BioPharma and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Mar 08, 2026

RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors with Losses to Contact the Firm - Financial Times

Mar 08, 2026

Mar 07, 2026